With Livmarli sales reaching $142 million during its second full year on the market, Mirum Pharmaceuticals’ rare liver disease treatment is off to a solid start in fulfilling its blockbuster potential ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical ...
Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor, is approved for the treatment of cholestatic pruritus in ...
Mirum Pharmaceuticals (MIRM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP Securities remains neutral on the stock ...
Mirum Pharmaceuticals (MIRM) is a good speculative biotech play to look into. The reason why I state that is because it has already received FDA approval for a drug from its pipeline. It received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback